-transparent.png){kind=logo}
Structure-based design of inhibitors of purine nucleoside phosphorylase. 3. 9-Arylmethyl derivatives of 9-deazaguanine substituted on the methylene group. 1993
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
BioCryst Pharmaceuticals, Inc., Birmingham, Alabama 35244.
X-ray crystallography and computer-assisted molecular modeling (CAMM) studies aided in the design of a potent series of mammalian purine nucleoside phosphorylase (PNP) inhibitors. Enhanced potency was achieved by designing substituted 9-(arylmethyl)-9-deazaguanine analogs that interact favorably with all three of the binding subsites of the PNP active site, namely the purine binding site, the hydrophobic pocket, and the phosphate binding site. The most potent PNP inhibitor prepared during our investigation, (S)-9-[1-(3-chlorophenyl)-2-carboxyethyl]-9-deazaguanine (18b), was shown to have an IC50 of 6 nM, whereas the corresponding (R)-isomer was 30-fold less potent.
Related Publications
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
July 1994,
Journal of medicinal chemistry,
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
July 1995,
Acta crystallographica. Section D, Biological crystallography,
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
February 1993,
Farmaco (Societa chimica italiana : 1989),
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
July 2008,
Bioorganic & medicinal chemistry,
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
June 1994,
Drug design and discovery,
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
November 1986,
Federation proceedings,
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
August 1987,
Agents and actions,
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
March 2002,
Chemical & pharmaceutical bulletin,
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
April 2010,
The FEBS journal,
M D Erion, and
S Niwas, and
J D Rose, and
S Ananthan, and
M Allen, and
J A Secrist, and
Y S Babu, and
C E Bugg, and
W C Guida, and
S E Ealick
August 1995,
Inflammation research : official journal of the European Histamine Research Society ... [et al.],
